Validation of KRISHZYME Factor IIa Chromogenic Assay for Testing of Tinzaparin and Tinzaparin Injection
Poster Dec 07, 2017
DR AMITABHA DE
The inhibitory effect of anti-thrombin III (AT-III) on thrombin, factor IIa and other coagulation serine proteases in plasma is increased several thousand-fold by Tinzaparin. This inhibition accounts for the anticoagulant effect of Tinzaparin.
The quantitative determination of Tinzaparin levels by the measurement of their anti-IIa activity is a necessary tool for monitoring treatment efficacy.
Presence of Tinzaparin catalyzes the reaction between factor IIa and AT-III. The factor IIa inhibition test is the most useful assay covering the widest variety of Tinzaparin preparations.
In the assay, the rate of factor IIa inhibition is directly proportional to the Tinzaparin concentration since both factor IIa and AT-III are in excess. The residual factor IIa activity is inversely proportional to the Tinzaparin concentration.
The assay was validated using Tinzaparin Sodium EPRS.
The assay kits manufactured by KRISHGEN BIOSYSTEMS are validated Chromogenic Assays for the determination of Tinzaparin using anti-lla activity in human plasma successfully met all standard assay-validation parameters and were suitable for use in bioequivalence studies.
Genome-wide association studies (GWAS) have identified more than 100 genetic loci associated with type 2 diabetes. The majority of these are located in the intergenic or intragenic regions suggesting that the implicated variants may alter chromatin conformation. This, in turn, is likely to influence the expression of nearby or more remotely located genes to alter beta cell function. At present, however, detailed molecular and functional analyses are still lacking for most of these variants. We recently analysed one of these loci and mapped five causal variants in an islet-specific enhancer cluster within the STARD10 gene locus. Here, we aimed to understand how these causal variants influence b-cell function by alteration of the chromatin structure of enhancer clusterREAD MORE
This abstract discusses three cases of pediatric heart transplant patients who suffered from parvovirus (B19) infection. Of these patients, two ( B & C) responded well to standard intravenous Ig therapy. Patient A however, did not respond to standard treatment and was begun on subcutaneous Ig, which effectively diminished his viral load. Thus, subcutaneous Ig infusions might serve as a second line treatment for transplant patients with parvovirus who do not respond well to the standard approach.READ MORE